Hikma Pharmaceuticals Past Earnings Performance
Past criteria checks 3/6
Hikma Pharmaceuticals's earnings have been declining at an average annual rate of -5.1%, while the Pharmaceuticals industry saw earnings growing at 3.4% annually. Revenues have been growing at an average rate of 7.3% per year. Hikma Pharmaceuticals's return on equity is 15.6%, and it has net margins of 12%.
Key information
-5.10%
Earnings growth rate
-3.49%
EPS growth rate
| Pharmaceuticals Industry Growth | 14.12% |
| Revenue growth rate | 7.33% |
| Return on equity | 15.62% |
| Net Margin | 12.00% |
| Next Earnings Update | 06 Aug 2026 |
Recent past performance updates
Recent updates
Narrative Update • Jun 18
HIK: Manufacturing Expansion And Steady Outlook Will Support Future Re Rating
Hikma Pharmaceuticals’ analyst price target has been held steady at £18.74, as analysts point to unchanged assumptions for fair value, discount rate, revenue growth, profit margin and future P/E as the basis for maintaining their view. What’s in the News for Hikma Pharmaceuticals Hikma Pharmaceuticals announced plans to invest $267 million to expand manufacturing operations in Columbus and Bedford, Ohio, with a total of 350 new jobs expected, pending approval of economic development incentives.Narrative Update • Jun 03
HIK: Index Change And Buyback Will Support Future Re Rating
Analysts have reduced their price target on Hikma Pharmaceuticals from £23.00 to £18.00, reflecting updated views on the stock while maintaining broadly consistent long term assumptions around fair value, discount rate, growth, margins and future P/E. What's in the News Hikma Pharmaceuticals USA Inc.Narrative Update • May 18
HIK: Buyback And Index Move Will Support Future Re Rating
Narrative update Hikma Pharmaceuticals' analyst price targets have been reset lower, with updates such as the move from £23.00 to £18.00 and from £24.00 to £20.00, as analysts factor in a slightly higher discount rate and modestly adjusted long term valuation assumptions while maintaining broadly constructive views on the stock. Analyst Commentary Recent Street research on Hikma Pharmaceuticals points to a recalibration of valuation, with price targets reduced but positive ratings maintained, including an Overweight rating from JPMorgan.Narrative Update • May 03
HIK: Buyback Plan And Index Shift Will Support Future Re Rating
Analysts have trimmed their fair value estimate for Hikma Pharmaceuticals to about £18.84 from £19.17, reflecting reduced price targets to £18.00 and £20.00 as they factor in slightly lower assumed revenue growth, profit margin and future P/E expectations. Analyst Commentary Bullish Takeaways Bullish analysts continue to see upside, keeping positive ratings in place even as price targets are trimmed to £18.00 and £20.00, which still sit above the revised fair value estimate of about £18.84.Narrative Update • Apr 19
HIK: Index Move And Buyback Plan Will Support Future Re Rating
Narrative Update: Hikma Pharmaceuticals The analyst price target for Hikma Pharmaceuticals has been reset towards a lower Street range, with recent cuts to £18.00 and £20.00. These figures inform a modestly higher fair value estimate of £19.17, supported by analysts referencing updated assumptions on revenue growth, profit margins and future P/E levels.Narrative Update • Apr 02
HIK: Buyback Plan And Leadership Changes Will Support Future Re Rating
Hikma Pharmaceuticals' updated fair value estimate has edged down slightly to £19.02 per share from £19.06. This reflects a series of reduced analyst price targets between £1,600 and £2,000, along with their increased focus on management uncertainty, strategic direction, and a more conservative P/E outlook.Narrative Update • Mar 19
HIK: Buyback Plan And Leadership Changes Will Support Future Re Rating
The analyst price target for Hikma Pharmaceuticals has been reduced by £1.41 per share. This change reflects updated fair value assumptions and ongoing analyst concerns around management visibility, strategic direction, and the near-term earnings outlook.
New Narrative • Mar 14
Injectable Expansion And MENA Scale Will Shape A Cautious Yet Steady Outlook
Catalysts About Hikma Pharmaceuticals Hikma Pharmaceuticals develops and supplies generic and branded medicines, including injectables, across MENA and the US. What are the underlying business or industry changes driving this perspective?Narrative Update • Mar 05
HIK: Leadership Change And Buyback Plan Will Support Future Re Rating Potential
Analysts have trimmed their price expectations for Hikma Pharmaceuticals, with our updated fair value moving from £21.82 to £20.47. This reflects recent cuts to Street targets to £2,000 and £1,600, as well as increased caution around growth, margins and the P/E investors may be willing to pay.
New Narrative • Feb 28
Rising CMO And Injectable Pipelines Will Support A Stronger Long Term Outlook
Catalysts About Hikma Pharmaceuticals Hikma Pharmaceuticals develops, manufactures, and supplies branded, generic, and injectable medicines across MENA, Europe, and North America. What are the underlying business or industry changes driving this perspective?Narrative Update • Feb 18
HIK: Leadership Change And Execution On Plans Will Support Re Rating Potential
Analysts have trimmed their fair value estimate for Hikma Pharmaceuticals from about £22.14 to £21.82, citing a slightly higher discount rate and lower future P/E assumptions following recent research that highlights uncertainty around management, strategy and potential catalysts. Analyst Commentary Recent research reflects a cautious tone on Hikma Pharmaceuticals, with the downgrade in rating and a £16.00 price target framed around execution risk and limited near term triggers for a re rating.Narrative Update • Feb 04
HIK: Leadership Reset And New Guidance Will Support Earnings Outlook
Analysts have adjusted their price targets for Hikma Pharmaceuticals within a wide £1,600 to £2,400 range, reflecting differing views on management clarity, strategic direction, and available catalysts for the shares. Analyst Commentary Recent research on Hikma Pharmaceuticals shows a split between analysts who see upside potential and those who are more cautious, which helps explain the wide spread in price targets.Narrative Update • Jan 21
HIK: Leadership Reset And 2030 Revenue Aim Will Underpin Earnings Outlook
Hikma Pharmaceuticals' updated fair value estimate has inched from £21.99 to £22.14 per share, reflecting mixed analyst views, as some raise price targets into the £23.00 range while others turn more cautious with Underweight ratings around £16.00 and cite uncertainty around management, strategy, and the outlook. Analyst Commentary Recent Street research on Hikma Pharmaceuticals highlights a clear split in opinion, with some analysts focusing on potential upside in execution and growth, while others flag risks around management direction and near term catalysts.Narrative Update • Jan 07
HIK: Leadership Reset And 2030 Revenue Ambition Will Support Earnings Outlook
Analysts have reduced their fair value estimate for Hikma Pharmaceuticals from £22.66 to £22.00 per share, reflecting a combination of more cautious views on management, strategy and catalysts, together with recent recalibrations of price targets across covering banks. Analyst Commentary Recent Street research on Hikma Pharmaceuticals shows a split between more cautious and more optimistic voices, with differing price targets and ratings feeding into the reduced fair value estimate.Narrative Update • Dec 14
HIK: US Approvals And Pipeline Expansion Will Drive Earnings Outlook Higher
Hikma Pharmaceuticals' analyst price target has been moderately revised as analysts balance a tighter fair value estimate of about $22.66 with slightly stronger expectations for revenue growth, margins, and supportive recent target changes in the 2,300 to 2,510 GBp range. Analyst Commentary Analyst commentary on Hikma Pharmaceuticals reflects a broadly constructive stance on the company, with recent target moves clustering within a relatively tight range and signaling confidence in the sustainability of its growth profile.Analysis Article • Dec 01
Market Cool On Hikma Pharmaceuticals PLC's (LON:HIK) Earnings
Hikma Pharmaceuticals PLC's ( LON:HIK ) price-to-earnings (or "P/E") ratio of 12.3x might make it look like a buy right...Narrative Update • Nov 27
HIK: Earnings Outlook Will Improve Following US Market Approval
Hikma Pharmaceuticals' analyst price target was revised modestly lower, from £23.55 to £23.36 per share. Analysts adjusted expectations reflecting a mix of target increases and decreases among recent Street research.Narrative Update • Nov 13
HIK: Shares Will Benefit From U S Approval And Profitability Improvements
Analysts have slightly reduced their fair value estimate for Hikma Pharmaceuticals from £25.40 to £23.55. This reflects modest downward adjustments to near-term price targets along with updated assumptions for discount rates, growth, and margins.Narrative Update • Oct 29
Expanded US Market Access Will Drive Momentum Amid Regulatory Headwinds
Hikma Pharmaceuticals' analyst price target was slightly raised to £25.40 from £25.02, as analysts cite updated growth and profitability forecasts. This comes despite recent downward adjustments in individual firm targets.Analysis Article • Oct 27
Hikma Pharmaceuticals (LON:HIK) Has A Somewhat Strained Balance Sheet
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysis Article • Sep 10
Do Hikma Pharmaceuticals' (LON:HIK) Earnings Warrant Your Attention?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Narrative Update • Sep 04
US, Europe, And MENA Expansion Will Boost Global Pharmaceutical Demand
Hikma Pharmaceuticals’ Future P/E ratio has dropped sharply, indicating improved valuation relative to earnings expectations, while revenue growth forecasts remain steady, resulting in the consensus price target edging down slightly from £25.17 to £25.02. What's in the News Hikma maintained full-year 2025 group revenue growth guidance of 4–6%, with core operating profit expected at $730–770 million; injectable segment revenue growth is guided at 7–9%, branded revenue at 6–7%, and Rx revenue broadly flat versus 2024.Analysis Article • Aug 02
Earnings Tell The Story For Hikma Pharmaceuticals PLC (LON:HIK)
With a median price-to-earnings (or "P/E") ratio of close to 16x in the United Kingdom, you could be forgiven for...Analysis Article • Jun 19
Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Analysis Article • Apr 08
Investors Appear Satisfied With Hikma Pharmaceuticals PLC's (LON:HIK) Prospects
There wouldn't be many who think Hikma Pharmaceuticals PLC's ( LON:HIK ) price-to-earnings (or "P/E") ratio of 14x is...Analysis Article • Mar 17
Here's Why Hikma Pharmaceuticals (LON:HIK) Can Manage Its Debt Responsibly
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
New Narrative • Mar 10
R&D Investments And Xellia Acquisition Will Expand Product Pipeline And Revenue Prospects
Strategic R&D investments and the acquisition of Xellia are expected to enhance Hikma's product pipeline, manufacturing capabilities, and revenue growth.Analysis Article • Nov 11
Hikma Pharmaceuticals PLC's (LON:HIK) P/E Is On The Mark
Hikma Pharmaceuticals PLC's ( LON:HIK ) price-to-earnings (or "P/E") ratio of 18.4x might make it look like a sell...Analysis Article • Oct 24
Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Aug 11
Hikma Pharmaceuticals PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Hikma Pharmaceuticals PLC ( LON:HIK ) just released its latest half-yearly results and things are looking bullish...Analysis Article • Aug 01
Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 36% Below Their Intrinsic Value Estimate
Key Insights Hikma Pharmaceuticals' estimated fair value is UK£29.88 based on 2 Stage Free Cash Flow to Equity Hikma...Analysis Article • Apr 24
Is Hikma Pharmaceuticals PLC (LON:HIK) Trading At A 29% Discount?
Key Insights Hikma Pharmaceuticals' estimated fair value is UK£25.52 based on 2 Stage Free Cash Flow to Equity Hikma...Analysis Article • Apr 02
Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Feb 25
Hikma Pharmaceuticals PLC's (LON:HIK) Share Price Matching Investor Opinion
With a price-to-earnings (or "P/E") ratio of 30.6x Hikma Pharmaceuticals PLC ( LON:HIK ) may be sending very bearish...Revenue & Expenses Breakdown
Revenue & Expenses Breakdown
How Hikma Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 25 | 3,349 | 402 | 666 | 151 |
| 30 Sep 25 | 3,283 | 387 | 662 | 152 |
| 30 Jun 25 | 3,216 | 371 | 658 | 153 |
| 31 Mar 25 | 3,172 | 365 | 659 | 147 |
| 31 Dec 24 | 3,127 | 359 | 660 | 141 |
| 30 Sep 24 | 3,072 | 322 | 656 | 144 |
| 30 Jun 24 | 3,017 | 285 | 651 | 146 |
| 31 Mar 24 | 2,946 | 238 | 642 | 148 |
| 31 Dec 23 | 2,875 | 190 | 632 | 149 |
| 30 Sep 23 | 2,803 | 168 | 619 | 144 |
| 30 Jun 23 | 2,731 | 146 | 606 | 139 |
| 31 Mar 23 | 2,624 | 167 | 604 | 142 |
| 31 Dec 22 | 2,517 | 188 | 601 | 144 |
| 30 Sep 22 | 2,534 | 267 | 593 | 149 |
| 30 Jun 22 | 2,550 | 346 | 585 | 153 |
| 31 Mar 22 | 2,552 | 384 | 573 | 148 |
| 31 Dec 21 | 2,553 | 421 | 561 | 143 |
| 30 Sep 21 | 2,489 | 444 | 535 | 139 |
| 30 Jun 21 | 2,425 | 467 | 509 | 134 |
| 31 Mar 21 | 2,383 | 449 | 508 | 136 |
| 31 Dec 20 | 2,341 | 431 | 506 | 137 |
| 30 Sep 20 | 2,317 | 472 | 503 | 134 |
| 30 Jun 20 | 2,292 | 513 | 500 | 130 |
| 31 Mar 20 | 2,250 | 500 | 494 | 128 |
| 31 Dec 19 | 2,207 | 486 | 487 | 126 |
| 30 Sep 19 | 2,173 | 424 | 481 | 128 |
| 30 Jun 19 | 2,138 | 361 | 475 | 129 |
| 31 Mar 19 | 2,104 | 322 | 471 | 124 |
| 31 Dec 18 | 2,070 | 282 | 467 | 118 |
| 30 Sep 18 | 2,045 | -262 | 464 | 110 |
| 30 Jun 18 | 2,020 | -806 | 460 | 102 |
| 31 Mar 18 | 1,978 | -824 | 467 | 109 |
| 31 Dec 17 | 1,936 | -843 | 474 | 115 |
| 30 Sep 17 | 1,950 | -338 | 462 | 122 |
| 30 Jun 17 | 1,963 | 166 | 450 | 129 |
| 31 Mar 17 | 1,957 | 161 | 440 | 128 |
| 31 Dec 16 | 1,950 | 155 | 429 | 126 |
| 30 Sep 16 | 1,782 | 166 | 411 | 100 |
| 30 Jun 16 | 1,613 | 176 | 392 | 73 |
| 31 Mar 16 | 1,527 | 214 | 372 | 55 |
| 31 Dec 15 | 1,440 | 252 | 352 | 36 |
| 30 Sep 15 | 1,450 | 248 | 346 | 46 |
| 30 Jun 15 | 1,460 | 243 | 339 | 56 |
Quality Earnings: HIK has high quality earnings.
Growing Profit Margin: HIK's current net profit margins (12%) are higher than last year (11.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HIK's earnings have declined by 5.1% per year over the past 5 years.
Accelerating Growth: HIK's earnings growth over the past year (12%) exceeds its 5-year average (-5.1% per year).
Earnings vs Industry: HIK earnings growth over the past year (12%) did not outperform the Pharmaceuticals industry 33.7%.
Return on Equity
High ROE: HIK's Return on Equity (15.6%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/19 20:35 |
| End of Day Share Price | 2026/06/19 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hikma Pharmaceuticals PLC is covered by 27 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sidhartha Modi | Barclays |
| James Gordon | Barclays |
| Beatrice Fairbairn | Berenberg |